UK Group Pushes for HTAs to Review More Biosimilars

The UK’s National Institute for Health and Clinical Excellence (NICE) and other health technology assessment (HTA) bodies should fully assess biosimilars for clinical and cost effectiveness, the Association for British Pharmaceutical Industries (ABPI) says.
Generic Line